Everest Medicines Announces First Patient Dosed with EVM16, Its First Internally Developed Personalized mRNA Cancer Vaccine
* The first patient has been dosed with EVM16 at Peking University Cancer Hospital, marking a major milestone as Everest's proprietary AI-based tumor neoantigen prediction algorithm and clinically validated mRNA platform progress into human trials. * In preclinical studies, EVM16 demonstrated...
Everest Medicines to Hold Investor Calls with Updates on mRNA Therapeutic Vaccine Programs
SHANGHAI, Feb. 28, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines, today announced that it will hold investor...
Everest Medicines Presents Complete Maintenance Period Data for Etrasimod at ECCO 2025
* Data confirms significant clinical and endoscopic benefits of etrasimod 2mg after 40 weeks of maintenance treatment * Etrasimod demonstrates robust efficacy across multiple endpoints, including mucosal healing, endoscopic normalization, and histological remission * Safety profile remains c...
Everest Medicines to Announce Full-Year 2024 Financial Results on March 26, 2025
SHANGHAI, Feb. 25, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its financial res...
Everest Medicines Announces the First Prescription of VELSIPITY® in the Greater Bay Area, Officially Benefiting Mainland China Patients
SHANGHAI, Dec. 18, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first prescription for VELSI...
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY® by the National Medical Products Administration of China for the Treatment of Moderately to Severely Active Ulcerative Colitis
SHANGHAI, Dec. 17, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the National Medical Products Ad...
Everest Medicines Announces the First Prescription of VELSIPITY® Issued in Macau, Officially Beginning to Benefit Asian Patients
SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first prescription of VELSIP...
Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy
* Patients in the low-dose cohort who have completed 36 weeks of treatment, 9 out of 11 (81.8%) achieved overall clinical remission and 10 out of 11 (91%) achieved immunological complete remission. * In the high dose cohort, 6 out of 7 (85.7%) patients achieved overall clinical remission and ...
Everest Medicines Announces Acceptance of VELSIPITY® New Drug Application in Hong Kong
SHANGHAI, Dec. 2, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that Department of Health of the Gover...
Everest Medicines Announces NEFECON®, the World's First Approved Treatment for IgA Nephropathy, is Included in China's National Reimbursement Drug List
SHANGHAI, Nov. 28, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that NEFECON® has been included in the...
Everest Medicines to Hold Investor Calls on Data Results from EVER001 Phase 1b/2a Clinical Study in Primary Membranous Nephropathy
SHANGHAI, Nov. 27, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will hold investor calls on t...
Two In Vitro Studies on Eravacycline (XERAVA®) Presented at IDWeek, Demonstrating Its Sustained and Robust Antimicrobial Activity
SHANGHAI, Nov. 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that data on its critical-care, anti...
Everest Medicines Announces NEFECON® Has Received Full Approval from South Korea's Ministry of Food and Drug Safety (MFDS) for the Treatment of Primary IgA Nephropathy
SHANGHAI, Nov. 19, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that NEFECON® has received full appro...
Everest Medicines Announces the Launch of VELSIPITY® in the Guangdong-Hong Kong-Macau Greater Bay Area, Offering a New Option for Moderately to Severely Active Ulcerative Colitis Patients
SHANGHAI, Oct. 25, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that, through the "Hong Kong and Ma...
Everest Medicines Announces Positive Results of Complete Chinese Subpopulation Data from the NEFECON® Global Phase 3 NefIgArd Clinical Trial Published in "Kidney 360" Magazine
SHANGHAI, Oct. 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the "Kidney 360" magazine has pu...
Everest Medicines Announces Taiwan TFDA Approval of NEFECON® for the Treatment of Primary IgA Nephropathy
SHANGHAI , Oct. 21, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announces that the Taiwan Food and Drug Admini...
Everest Medicines Announces Interim Results for First Half of 2024
SHANGHAI, Aug. 28, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced its interim results for the first half of 2024 a...
Everest Medicines Announces the Initiation of an Investigator-Initiated Clinical Trial (IIT) for Personalized mRNA Cancer Vaccine Program EVM16
SHANGHAI, Aug. 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced the launch of an Investigator-Initiat...
Everest Medicines to Announce 2024 Interim Results on August 28, 2024
SHANGHAI, Aug. 6, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its interim result...
Everest Medicines Announces First Chinese Patient Dosed in Global Phase 2b PALIZADE Trial of Zetomipzomib in Lupus Nephritis
SHANGHAI, July 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first Chinese patient has be...
